The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR-T cell therapy: current limitations and potential strategies

(2021) Robert C. Sterner et al.   Blood Cancer Journal

Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.

(2021) Saad Zafar Usmani et al.   JOURNAL OF CLINICAL ONCOLOGY

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

(2021) Saad Z Usmani et al.   LANCET

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

(2021) Jesus G Berdeja et al.   LANCET

Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

(2020) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches

(2020) Nina Shah et al.   LEUKEMIA

Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN

(2020) Peter M Voorhees et al.   BLOOD

The BiTE (Bispecific T‐Cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types

(2020) Hermann Einsele et al.   CANCER

BCMA-targeted immunotherapy for multiple myeloma

(2020) Bo Yu et al.   Journal of Hematology & Oncology

Bispecifics, trispecifics, and other novel immune treatments in myeloma

(2020) Guido Lancman et al.   Hematology-American Society of Hematology Education Program

Daratumumab Plus Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

(2019) Ajai Chari et al.   BLOOD

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

(2019) Sagar Lonial et al.   LANCET ONCOLOGY

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B‐Cell Acute Lymphoblastic Leukemia

(2018) E. Dianne Pulte et al.   ONCOLOGIST

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

(2018) Shih-Feng Cho et al.   Frontiers in Immunology

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

(2018) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

(2017) S K Kumar et al.   LEUKEMIA

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

(2016) Sagar Lonial et al.   LANCET

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE